Comparative Pharmacology
Head-to-head clinical analysis: GARAMYCIN versus GENOPTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GARAMYCIN versus GENOPTIC.
GARAMYCIN vs GENOPTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis, leading to bacterial cell death.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Gentamicin 3-5 mg/kg/day IV or IM in 3 divided doses every 8 hours for serious infections; may use once-daily dosing (5 mg/kg IV every 24 hours) for certain indications.
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours in adults with normal renal function; prolonged in renal impairment (up to 40-50 hours in anuria).
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<2%).
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic